Clinical TrialMay 21, 2026, 05:31 PM
Crescent Biopharma to present CR-001 ASCEND trial data at ASCO; Q1 2027 data expected
AI Summary
Crescent Biopharma announced a trial in progress poster presentation for its ASCEND Phase 1/2 clinical trial of CR-001, a PD-1 x VEGF bispecific antibody, at the 2026 ASCO Annual Meeting. The global, open-label trial is evaluating CR-001 in various solid tumor types, including non-small cell lung cancer and gastrointestinal and gynecological cancers. The company anticipates initial proof-of-concept clinical data from the ASCEND trial in Q1 2027, with further data readouts for combination therapies expected in mid-2027.
Key Highlights
- CR-001 ASCEND Phase 1/2 trial poster to be presented at ASCO Annual Meeting (May 29-June 2).
- Initial proof-of-concept clinical data from ASCEND trial expected in Q1 2027.
- ASCEND trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal, and gynecological cancers.
- The global ASCEND trial is expected to enroll up to 290 patients.
- Initial data for CR-001 in combination with standard of care chemotherapy expected mid-2027.
- Initial data from China Phase 1/2 trial of CR-001 with Kelun-Biotech ADC expected mid-2027.
Price Impact
More from CBIO